Vycellix, Inc.: Vycellix Presents Proof-of-Concept Data for VY-UC Allogeneic Cell Therapy Platform at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting, Paris
Single-Step CD45-Engager Strategy Generates Immune-Privileged Cells with Abrogation of Host Cellular Immune Responses Being Developed to Eliminate the Need for Complex, Expensive Gene-Editing Approaches
Source: finanznachrichten.de